1.The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.
Huan LIU ; Xiaojie SU ; Lulu SI ; Lu LU ; Shibo JIANG
Protein & Cell 2018;9(7):596-615
A human immunodeficiency virus type-1 (HIV-1) vaccine which is able to effectively prevent infection would be the most powerful method of extinguishing pandemic of the acquired immunodeficiency syndrome (AIDS). Yet, achieving such vaccine remains great challenges. The membrane-proximal external region (MPER) is a highly conserved region of the envelope glycoprotein (Env) gp41 subunit near the viral envelope surface, and it plays a key role in membrane fusion. It is also the target of some reported broadly neutralizing antibodies (bNAbs). Thus, MPER is deemed to be one of the most attractive vaccine targets. However, no one can induce these bNAbs by immunization with immunogens containing the MPER sequence(s). The few attempts at developing a vaccine have only resulted in the induction of neutralizing antibodies with quite low potency and limited breadth. Thus far, vaccine failure can be attributed to various characteristics of MPER, such as those involving structure and immunology; therefore, we will focus on these and review the recent progress in the field from the following perspectives: (1) MPER structure and its role in membrane fusion, (2) the epitopes and neutralization mechanisms of MPER-specific bNAbs, as well as the limitations in eliciting neutralizing antibodies, and (3) different strategies for MPER vaccine design and current harvests.
AIDS Vaccines
;
chemistry
;
immunology
;
Antibodies, Neutralizing
;
immunology
;
HIV Antibodies
;
immunology
;
HIV Envelope Protein gp41
;
immunology
;
HIV-1
;
chemistry
;
immunology
;
Humans
2.Inhibitory effect of polysaccharides on the six-alpha-helix bundle formation of HIV gp41 protein.
Xiao-Yun WEN ; Shao-Yu WU ; Wei XU ; Li LV ; Shu-Wen LIU ; Jin-Jun RAO ; Jia-Jie ZHANG ; Guang-Fa WANG ; Shan-He WAN ; Shu-Guang WU
Journal of Southern Medical University 2007;27(10):1498-1500
OBJECTIVETo compare the in vitro inhibitory effect of expolysaccharides from Streptomyces, polysaccharides of Ganoderma lucidum and rice bran on six-alpha-helix bundle formation of HIV gp41 protein.
METHODSThe amount of six-alpha-helix bundle formed in the presence of N36 and C34 was tested by ELISA in response to treatments with different doses of polysaccharides.
RESULTSExpolysaccharides from Streptomyces potentially inhibited six-alpha-helix bundle formation with the effective concentration (IC(50)) of 145.48-/+7.25 mg /L. Polysaccharides of Ganoderma lucidum and rice bran showed no effect on the six-alpha-helix bundle formation.
CONCLUSIONExpolysaccharides from Streptomyces can inhibit the six-alpha-helix bundle formation of HIV gp41, whereas polysaccharides of Ganoderma lucidum and rice bran do not exhibit such activity.
HIV Envelope Protein gp41 ; chemistry ; Kinetics ; Oryza ; chemistry ; Polysaccharides ; pharmacology ; Protein Structure, Secondary ; drug effects ; Reishi ; chemistry ; Streptomyces ; chemistry
3.Expression, structure and antigenicity analysis of N51 derived from the N-terminal heptad repeat domain in gp41 of HIV-1 CRF07_BC strain.
Jiping SHAO ; Shibo JIANG ; Shuwen LIU
Journal of Southern Medical University 2012;32(12):1737-1740
OBJECTIVETo express N51 derived from the N-terminal heptad repeat (NHR) domain in gp41 of the HIV-1 CRF07_BC strain and analyze its molecular structure and antigenicity.
METHODSOverlapping PCR was used to amplify the DNA fragment encoding N51Fd gene, which was then subcloned into the vector pFUSE-hIgG1-Fc2. The construct was confirmed by DNA sequencing. The structure and antigenicity of the recombinant protein N51FdFc-BC were analyzed using bioinformatic software, circular dichroism, and Western blotting.
RESULTSA recombinant expression vector pFUSE/N51Fd-BC was successfully constructed. N51FdFc-BC recombinant protein with a relative molecular mass of about 35 000 was effectively expressed in mammalian 293T cells and could be recognized by rabbit antibodies against HIV-1 gp41 N/C peptides as shown by Western blotting. Bioinformatic analysis showed that the recombinant protein N51FdFc-BC, with a relative molecular mass of 34 315.1 and a PI of 7.59, formed a secondary structure of random coil to allow its interactions as an antigen with antibodies. Circular dichroism measurement confirmed the random coil structure of N51FdFc-BC protein.
CONCLUSIONThe recombinant protein N51FdFc-BC has a random coil structure and can be used as an immunogen for development of HIV-1 subunit vaccine.
Amino Acid Sequence ; HEK293 Cells ; HIV Envelope Protein gp41 ; genetics ; immunology ; HIV-1 ; chemistry ; genetics ; Humans ; Protein Structure, Secondary ; Recombinant Proteins ; genetics ; immunology ; Sequence Analysis, DNA
4.A non-infectious and quantitative cell-based bioassay for screening HIV entry inhibitors targeting HIV envelope proteins.
Min-min LI ; Cheng-lai XIA ; Qin-chao MAO ; Shi-bo JIANG ; Shu-wen LIU
Journal of Southern Medical University 2010;30(5):941-944
OBJECTIVETo develop an objective bioassay for quantitative detection of HIV-induced cell-cell fusion for screening HIV entry inhibitors.
METHODSHL2/3 cells expressing HIV envelope proteins gp120/gp41, Tat, and other HIV proteins were co-cultured with HeLa-CD4-LTR-beta-gal cells expressing CD4 receptor and HIV LTR triggered reporter gene beta-galactosidase. The enzyme activities of beta-galactosidase were detected by a chromogenic substrate, chlorophenol red-beta-galactopyranoside (CPRG). Specific HIV entry inhibitors were used to validate the established detecting method.
RESULTSNo syncytium was formed by mixing HL2/3 and HeLa-CD4-LTR-beta-gal cells. However, the membrane could be fused and the Tat expressed by HL2/3 cells could bind to HIV LTR on HeLa-CD4-LTR-beta-gal cells and trigger the expression of beta-galactosidase. CPRG allowed quantitative and sensitive detection of the activity of beta-galactosidase. Further studies showed that HIV entry inhibitors could inhibit the activity of beta-galactosidase in a dose-dependent manner.
CONCLUSIONWe have developed a simple, cheap, objective and quantitative non-infectious cell-cell fusion bioassay that can be used to screen for anti-HIV agents targeting the virus entry from natural and synthetic compound libraries.
Biological Assay ; Cell Fusion ; Cell Line ; Coculture Techniques ; Drug Evaluation, Preclinical ; methods ; HIV Envelope Protein gp120 ; metabolism ; HIV Envelope Protein gp41 ; metabolism ; HIV Fusion Inhibitors ; chemistry ; pharmacology ; Humans ; beta-Galactosidase ; metabolism
5.Conserved arginine residue in the membrane-spanning domain of HIV-1 gp41 is required for efficient membrane fusion.
Yufei LONG ; Fanxia MENG ; Naoyuki KONDO ; Aikichi IWAMOTO ; Zene MATSUDA
Protein & Cell 2011;2(5):369-376
Despite the high mutation rate of HIV-1, the amino acid sequences of the membrane-spanning domain (MSD) of HIV-1 gp41 are well conserved. Arginine residues are rarely found in single membrane-spanning domains, yet an arginine residue, R(696) (the numbering is based on that of HXB2), is highly conserved in HIV-1 gp41. To examine the role of R(696), it was mutated to K, A, I, L, D, E, N, and Q. Most of these substitutions did not affect the expression, processing or surface distribution of the envelope protein (Env). However, a syncytia formation assay showed that the substitution of R(696) with amino acid residues other than K, a naturally observed mutation in the gp41 MSD, decreased fusion activity. Substitution with hydrophobic amino acid residues (A, I, and L) resulted in a modest decrease, while substitution with D or E, potentially negatively-charged residues, almost abolished the syncytia formation. All the fusion-defective mutants showed slower kinetics with the cell-based dual split protein (DSP) assay that scores the degree of membrane fusion based on pore formation between fusing cells. Interestingly, the D and E substitutions did show some fusion activity in the DSP assays, suggesting that proteins containing D or E substitutions retained some fusion pore-forming capability. However, nascent pores failed to develop, due probably to impaired activity in the pore enlargement process. Our data show the importance of this conserved arginine residue for efficient membrane fusion.
Amino Acid Substitution
;
Animals
;
Arginine
;
chemistry
;
metabolism
;
Cell Line
;
Cercopithecus aethiops
;
HIV Envelope Protein gp41
;
chemistry
;
metabolism
;
HIV-1
;
metabolism
;
Humans
;
Kinetics
;
Membrane Fusion
;
physiology
;
Mutation
;
Protein Structure, Tertiary
6.The current progress in the development of HIV-1 fusion inhibitors.
Wei-guo SHI ; Qi-yan JIA ; Ke-liang LIU
Acta Pharmaceutica Sinica 2010;45(2):184-193
HIV-1 fusion inhibitors are a new class of anti-HIV compounds, which block the entry of HIV into target cells through preventing the fusion between viral and cell plasma membrane and thus interrupt the initial steps of viral replication. T-20 (enfuvirtide), which has been clinically approved as the first fusion inhibitor of HIV-1 by U.S. FDA in 2003, can suppress replication of HIV variants with multi-drug resistance to reverse transcriptase and protease inhibitors. Peptides and small molecules display potent anti-HIV fusion activities by targeting gp41 thus inhibit its fusogenic function. In recent years, with the development of studies on the molecular mechanism of HIV membrane fusion process and the function of gp41, many new fusion inhibitors are found and some have been in advanced clinical trials. This review discusses recent progress in the development of HIV-1 fusion inhibitors targeting the gp41.
Anti-HIV Agents
;
chemical synthesis
;
chemistry
;
pharmacology
;
Drug Resistance, Multiple
;
HIV Envelope Protein gp41
;
chemical synthesis
;
chemistry
;
pharmacology
;
HIV Fusion Inhibitors
;
chemical synthesis
;
chemistry
;
pharmacology
;
HIV Infections
;
drug therapy
;
HIV-1
;
drug effects
;
physiology
;
Humans
;
Peptide Fragments
;
chemical synthesis
;
chemistry
;
pharmacology
;
Peptides
;
chemical synthesis
;
chemistry
;
pharmacology
;
Recombinant Fusion Proteins
;
chemical synthesis
;
chemistry
;
pharmacology
;
Virus Replication
;
drug effects
;
alpha 1-Antitrypsin
;
chemical synthesis
;
chemistry
;
pharmacology
7.Structure-activity relationships of anti-HIV-1 peptides with disulfide linkage between D- and L-cysteine at positions i and i+3, respectively, derived from HIV-1 gp41 C-peptide.
Myung Kyu LEE ; Hee Kyung KIM ; Tae Young LEE ; Kyung Soo HAHM ; Kil Lyong KIM
Experimental & Molecular Medicine 2006;38(1):18-26
The constrained alpha-helical structure of a C-peptide is useful for enhancing anti-HIV-1 activity. The i and i+3 positions in an alpha-helical structure are located close together, therefore D-Cys (dC) and L-Cys (C) were introduced at the positions, respectively, to make a dC-C disulfide bond in 28mer C-peptides. Accordingly, this study tested whether a dC-C disulfide bond would increase the alpha-helicity and anti-HIV-1 activity of peptides. A C-peptide can be divided into three domains, the N-terminal hydrophobic domain (HPD), middle interface domain (IFD), and C-terminal hydrogen domain (HGD), based on the binding property with an N-peptide. In general, the dC-C modifications in HPD enhanced the anti-HIV-1 activity, while those in IFD and HGD resulted in no or much less activity. The modified peptides with no activity clearly showed much less alpha-helicity than the native peptides, while those with higher activity showed an almost similar or slightly increased alpha-helicity. Therefore, the present results suggest that the introduction of a dC-C bridge in the N-terminal hydrophobic domain of a C-peptide may be useful for enhancing the anti-HIV-1 activity.
Amino Acid Sequence
;
Anti-HIV Agents/chemical synthesis/*chemistry/isolation & purification/*pharmacology
;
Cell Line
;
Circular Dichroism
;
Cysteine/chemistry
;
Disulfides/chemistry
;
HIV Envelope Protein gp41/*chemistry
;
HIV-1/*drug effects/growth & development
;
Humans
;
Inhibitory Concentration 50
;
Models, Molecular
;
Molecular Sequence Data
;
Peptides/chemical synthesis/*chemistry/isolation & purification/*pharmacology
;
Protein Structure, Secondary
;
Protein Structure, Tertiary
;
Research Support, Non-U.S. Gov't
;
Structure-Activity Relationship
8.HIV entry inhibitors: progress in development and application.
Wei-hong LAI ; Li HUANG ; Chin-ho CHEN
Acta Pharmaceutica Sinica 2010;45(2):131-140
This review discusses recent progress in the development of anti-HIV agents, with emphasis on small molecule HIV-1 entry inhibitors. The entry inhibitors primarily target HIV-1 envelope glycoproteins or the cellular receptors, CD4 and chemokine receptors. Two of the entry inhibitors, enfuvirtide and maraviroc, have been approved by the US FDA for AIDS therapy. The drug resistance associated with some of the entry inhibitors will also be discussed.
Anti-HIV Agents
;
chemistry
;
pharmacology
;
therapeutic use
;
CCR5 Receptor Antagonists
;
CD4 Antigens
;
drug effects
;
Cyclohexanes
;
pharmacology
;
therapeutic use
;
Drug Resistance, Viral
;
HIV Envelope Protein gp120
;
pharmacology
;
HIV Envelope Protein gp41
;
pharmacology
;
therapeutic use
;
HIV Fusion Inhibitors
;
chemistry
;
pharmacology
;
therapeutic use
;
HIV Infections
;
drug therapy
;
HIV-1
;
drug effects
;
Humans
;
Molecular Structure
;
Peptide Fragments
;
pharmacology
;
therapeutic use
;
Receptors, CCR5
;
physiology
;
Receptors, CXCR4
;
antagonists & inhibitors
;
Receptors, Chemokine
;
drug effects
;
Triazoles
;
pharmacology
;
therapeutic use
9.Association of variations of NAb 2F5 and 4E10 epitopes and disease progression in Chinese antiretroviral treatment-naïve patients infected with HIV-1 clade B'.
Xiao-Li ZHANG ; Xiao-Xu HAN ; Di DAI ; Ming-Jia BAO ; Dong-Bing XU ; Zi-Ning ZHANG ; Ya-Nan WANG ; Min ZHAO ; Tristan BICE ; Yong-Jun JIANG ; Hong SHANG
Chinese Medical Journal 2010;123(23):3406-3411
BACKGROUNDStudies on human immunodeficiency virus type 1 (HIV-1) vaccines have recently focused on targeting the conserved neutralizing epitopes 2F5 and 4E10, and hence it is important to understand the extent of mutations in these two viral epitopes. Here, we investigated the amino acid mutations in epitopes of 2F5 (ELDKWA, HIV-1 HXB2 env 662 - 667 aa) and 4E10 (NWFDIT, HIV-1 HXB2 env 671 - 676 aa) in the membrane proximal-external region of gp41 from clade B' HIV-1-infected individuals living in Henan province, China. We also examined the frequency of a mutation and its relation to disease progression.
METHODSA cohort of 54 treatment-naïve HIV-1-infected individuals was recruited in this study, and 16 individuals were selected for a short-term longitudinal study on sequence evolution. The HIV-1 env gp41 gene was amplified, cloned, and sequenced, and predicted amino acid sequences were aligned for analysis.
RESULTSThe mutations E662A and K665E on the 2F5 epitope and N671S and T676S on the 4E10 epitope were seen. Simultaneous RNA sequencing showed some discrepancies with proviral DNA sequences. In our longitudinal study, mutation levels of these two neutralizing epitopes were low but diverse and persistent. The frequencies of mutations within the 4E10 peptide NWFDIT in slow progressors were noticeably lower than those in AIDS patients (P < 0.05).
CONCLUSIONSAntigenic variation of the neutralizing epitopes 2F5 and 4E10 is limited in subtype B' infection, and that 4E10 peptide mutation is correlated with disease progression. Monitoring epitope mutations will offer useful data for development of the candidate 2F5-like and 4E10-like antibodies to prevent and treat AIDS.
Acquired Immunodeficiency Syndrome ; drug therapy ; Adult ; Antibodies, Neutralizing ; genetics ; Asian Continental Ancestry Group ; genetics ; Disease Progression ; Epitopes ; genetics ; Evolution, Molecular ; HIV Antibodies ; genetics ; HIV Envelope Protein gp41 ; immunology ; HIV-1 ; immunology ; Humans ; Longitudinal Studies ; Middle Aged ; Mutation ; RNA, Viral ; blood ; chemistry
10.The newest developments in anti-HIV-1 drugs.
Acta Pharmaceutica Sinica 2010;45(2):194-204
In the two decades since AZT was first approved for clinical use in 1987, 24 additional antiretroviral agents have been approved. They include 7 nucleoside analogs, a nucleotide analog and 4 non-nucleoside reverse transcriptase inhibitors, 10 protease inhibitors, 2 entry inhibitors and an integrase inhibitor. More than 20 investigational agents are currently being studied in clinical trials. Highly active antiretroviral therapy (HAART), which involves a combination of anti-HIV-1 drugs, is extremely effective in suppressing HIV-1 replication and increasing CD4+ number and results in substantial reductions in HIV-1-related morbidity and mortality. In last 20 years, much has been learned about resistance to antiretroviral drugs, drug interactions and metabolic complications of antiviral drug use. Drugs are now selected on the basis of resistance tests and on the risk of specific drug complications in individual patients. As a result, decisions about the therapy of HIV/AIDS have become personalized and are made on a patient-by-patient basis. With appropriate medical management, a person with HIV-1 now has the possibility of a nearly normal life expectancy.
Anti-HIV Agents
;
adverse effects
;
pharmacology
;
therapeutic use
;
Antiretroviral Therapy, Highly Active
;
Cyclohexanes
;
chemistry
;
pharmacology
;
therapeutic use
;
Drug Resistance, Viral
;
HIV Envelope Protein gp41
;
chemistry
;
therapeutic use
;
HIV Fusion Inhibitors
;
chemistry
;
pharmacology
;
therapeutic use
;
HIV Infections
;
drug therapy
;
HIV Integrase Inhibitors
;
chemistry
;
pharmacology
;
therapeutic use
;
HIV Protease Inhibitors
;
chemistry
;
pharmacology
;
therapeutic use
;
HIV Reverse Transcriptase
;
chemistry
;
pharmacology
;
therapeutic use
;
HIV-1
;
drug effects
;
physiology
;
Humans
;
Molecular Structure
;
Peptide Fragments
;
chemistry
;
therapeutic use
;
Pyrrolidinones
;
chemistry
;
pharmacology
;
therapeutic use
;
Raltegravir Potassium
;
Saquinavir
;
chemistry
;
pharmacology
;
therapeutic use
;
Triazoles
;
chemistry
;
pharmacology
;
therapeutic use
;
Virus Replication
;
drug effects
;
Zidovudine
;
chemistry
;
pharmacology
;
therapeutic use